AIDSmeds: "Fewer people who took the integrase inhibitor Isentress (raltegravir) once-daily were able to control their HIV levels compared with people who took the drug twice-daily, as is currently recommended, according to a release from the drug’s maker Merck.
"Isentress was approved in 2007 to treat people with HIV resistant to most other antiretroviral drugs and in 2009 to treat people who were new to therapy. Given how quickly the body processes and eliminates Isentress, it was initially studied and approved as a twice-daily dose."
0 comments:
Post a Comment